GOLD 2024: a brief overview of key changes
Since 2001 (more than twenty years ago) the Global Initiative for Obstructive Lung Disease (GOLD) publishes and updates every year a document that recommends how to best diagnose and manage chronic obstructive pulmonary disease (COPD).(1) This is an enormous and continued team effort, so we want to start by acknowledging the dedication and hard work of all GOLD members through the years (www.goldcopd.org). The GOLD 2024 document has just been released and is available for free download in the GOLD website, together with a pocket guide and a teaching slide set.(2) Here we present a brief overview of what we think are the most relevant changes (or lack of) introduced in this 2024 edition of the GOLD recommendations.
To begin with, it is worth mentioning that, to avoid potential duplications and improve readability of the document, Chapter 3 (Evidence supporting prevention and maintenance therapy) and Chapter 4 (Management of stable COPD) in the GOLD 2023 document have now been merged into a single chapter (new Chapter 3 in GOLD 2024: Prevention and Management of COPD). Besides, the GOLD Science Committee identified a number of topics that, although already discussed in GOLD 2023, required and deserved further discussion. Accordingly, the following aspects about the diagnosis or management of COPD have been expanded and updated in GOLD 2024.
Puedes leer el artículo completo aquí: https://jornaldepneumologia.com.br/details/3908/en-US/gold-2024–a-brief-overview-of-key-changes
Authors: Alvar Agustí, Claus F. Vogelmeier.
Noticias relacionadas
Novedades GOLD 2025 – 19 Noviembre 2024. 17:30-19h
NOVEDADES GOLD 2025, Reunión mixta el próximo 19 de Noviembre 2024, de 17:30 a 19h. Asistencia gratuita, pero precisa registro on-line. Link de registro aquí.
GOLD Webinar · AI in Respiratory Medicine (GOLD Italy)
Artificial Intelligence in Respiratory Medicine GOLD Webinar · 6 de Mayo del 2024.
The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
The diagnosis of COPD requires the demonstration of non-fully reversible airflow limitation by spirometry in the appropriate clinical context.
Artículos
Gold
- 768778·Alvar Agusti, Claus F. Vogelmeier – GOLD 2024: a brief overview of key changes
- 768973·Marie Grasl, Alvar Agusti, Caspar Schiffers, Owat Sunanta, Marie-Kathrin Breyer, Sylvia Hartl, Robab Breye -Etiotypes of persistent airflow obstruction in the general population in different age bins
- 769385·GOLD 2023 Executive Summary: responses from the GOLD Scientific Committee
- 769699·Alvar Agustí et al.- GOLD 2023: What’s New, Doc?
COPD
- 759578·Alberto Papi et Al.-Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
Recuerda que puedes acceder a varios enlaces a artículos dentro de las categorías COPD y GOLD en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imagen creada desde la información aportada.